US Meningococcal Vaccines Market

ID: MRFR/Pharma/17885-HCR

100 Pages

Garvit Vyas

September 2025

US Meningococcal Vaccines Market Research Report: By Vaccine Type (Monovalent Vaccines, Multivalent Vaccines, Conjugate Vaccines), By Age Group (Infants, Children, Adolescents, Adults), By Administration Route (Intramuscular, Subcutaneous, Oral) and By Distribution Channel (Hospitals, Clinics, Pharmacies) - Forecast to 2035

US Meningococcal Vaccines Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

US Meningococcal Vaccines Market Summary

The United States Meningococcal Vaccines market is projected to grow from 1.02 billion USD in 2024 to 1.65 billion USD by 2035.

Key Market Trends & Highlights

US Meningococcal Vaccines Key Trends and Highlights

The market is expected to experience a compound annual growth rate (CAGR) of 4.47 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 1.65 billion USD, indicating robust growth potential.
In 2024, the market is valued at 1.02 billion USD, reflecting the current demand for meningococcal vaccines in the United States.
Growing adoption of meningococcal vaccines due to increased awareness of bacterial meningitis is a major market driver.

US Meningococcal Vaccines Market

CAGR

4.47%

Market Size & Forecast

2024 Market Size	1.02 (USD Billion)
2035 Market Size	1.65 (USD Billion)
CAGR (2025-2035)	4.47%

Major Players

Novartis, AstraZeneca, Merck, GlaxoSmithKline, CureVac, Moderna, Pfizer, Kamada, Amgen, Valneva, VBI Vaccines, Serum Institute of India, Bavarian Nordic, Sanofi Pasteur

US Meningococcal Vaccines Market Trends

The US Meningococcal Vaccines Market is witnessing several important trends driven by increasing awareness of meningococcal disease and the effectiveness of vaccination programs. A significant market driver includes the implementation of vaccination requirements for school entry, which has led to higher vaccination rates among adolescents.

The Centers for Disease Control and Prevention (CDC) recommend routine vaccination against meningococcal disease for teenagers, thus promoting accessibility and acceptance of these vaccines across various demographics. Additionally, recent attention to public health has underscored the importance of preventive measures against infectious diseases.

This aspect opens opportunities for innovative vaccine research and development, with a focus on improving vaccine formulations and delivery methods. The expansion of vaccination programs also creates opportunities for collaborations between public health authorities and private pharmaceutical companies, which can enhance outreach efforts and increase distribution efficiency.

Trends in the US are also reflecting a growing public interest in vaccine education and awareness campaigns, driven by various health organizations aiming to address vaccine hesitancy. The rise of digital health platforms and social media campaigns is facilitating the dissemination of accurate information about meningococcal vaccines.

Recent times have seen increased engagement in community immunization programs, further strengthening the commitment to boost vaccination coverage. This collaborative approach is crucial as it allows for better the understanding of meningococcal disease and its prevention, ultimately fostering a healthier population in the US.

Market Segment Insights

Meningococcal Vaccines Market Vaccine Type Insights

The US Meningococcal Vaccines Market is poised for growth, particularly in the Vaccine Type segment, which includes Monovalent Vaccines, Multivalent Vaccines, and Conjugate Vaccines. Monovalent Vaccines target a single serotype, proving essential in areas with a high prevalence of a specific strain, thereby serving as a frontline defense against targeted meningococcal infections.

This has made them an essential part of vaccination programs, especially for new cohorts like infants and young adults. Meanwhile, Multivalent Vaccines, which cover several serotypes within one shot, cater to broader immunity. This wider coverage is crucial as it enhances herd immunity and provides better protection against varying strains seen in different regions of the US.

Furthermore, Conjugate Vaccines are increasingly significant due to their innovative design, which links polysaccharides from the bacteria to proteins, significantly boosting the immune response particularly in infants and younger populations. This has had a profound impact on reducing incidence rates of invasive meningococcal disease across various demographic groups.

Each Vaccine Type plays a pivotal role in managing public health initiatives aimed at combating meningococcal diseases, supported by extensive Research and Development efforts to improve efficacy and safety. By understanding the dynamics and varying contributions of each Vaccine Type, stakeholders can better navigate the landscape of the US Meningococcal Vaccines Market and support informed decision-making in public health strategies.

Overall, the segment's ongoing evolution and adaptation reflect the critical need for effective vaccination strategies in safeguarding the health of the US population against meningococcal diseases.

Meningococcal Vaccines Market Age Group Insights

The Age Group segmentation within the US Meningococcal Vaccines Market plays a crucial role in understanding the distribution of immunizations across various demographics. Infants and children are particularly significant, as they represent the most vulnerable populations against meningococcal disease, with vaccination being critical for their protection.

Adolescents also represent a vital group for vaccination programs, as the incidence rates of meningococcal infections peak during these years, making timely immunization essential to control outbreaks. Adults, while experiencing lower incidence rates, still constitute an important population, especially due to increased recommendations for vaccinations among those with underlying health conditions or who are in close living quarters.

Overall, the US Meningococcal Vaccines Market statistics indicates a growing awareness regarding the necessity for vaccinations across all age groups, driven by health education initiatives and government policies. These trends highlight an ongoing effort to boost public health and protect vulnerable populations, ensuring that vaccination rates remain high enough to prevent the spread of meningococcal disease.

The diverse needs across these age groups underline the importance of tailored strategies in vaccination programs for effectively addressing the specific requirements of each demographic.

Meningococcal Vaccines Market Administration Route Insights

The Administration Route for the US Meningococcal Vaccines Market plays a crucial role in determining vaccine efficacy and patient compliance. This segment includes diverse methods such as Intramuscular, Subcutaneous, and Oral administration, each tailored to meet specific immunization needs and preferences.

Within this market, Intramuscular delivery is often favored due to its reliable absorption and strong immune response, making it the predominant choice among healthcare professionals. Meanwhile, Subcutaneous administration offers a less invasive option with potential for easier application, catering to specific demographics like infants and young children.

Oral vaccination, although less common in this category, presents an attractive alternative for improving compliance due to its ease of use. As public health initiatives in the United States strive toward increasing vaccination rates, understanding patient preferences and optimizing administration routes becomes crucial in addressing the meningococcal disease burden.

Trends such as the rising focus on user-friendly delivery systems and the clinical benefits of varied administration methods drive significant opportunities for growth in this segment, aligning with broader public health goals set forth by health authorities.

Meningococcal Vaccines Market Distribution Channel Insights

The Distribution Channel in the US Meningococcal Vaccines Market plays a crucial role in ensuring that vaccines reach the population effectively. The market can be differentiated into major channels such as Hospitals, Clinics, and Pharmacies.

Hospitals serve as integral hubs for vaccination, often facilitating extensive immunization campaigns and providing a higher volume of vaccinations, which significantly supports public health efforts. Clinics, on the other hand, offer more personalized care and accessibility, making them essential for reaching specific demographics, such as children and at-risk populations.

Pharmacies have emerged as a convenient option for many individuals seeking vaccinations, with their broad availability and flexible hours encouraging greater participation in immunization programs. Collectively, these distribution channels contribute to a robust framework that bolsters vaccination rates, addressing public health challenges and enhancing community protection against meningococcal disease.

Additionally, as the awareness of meningococcal diseases rises and vaccination programs expand, these channels are expected to adapt and evolve, reflecting changing consumer preferences and healthcare demands in the US.

Get more detailed insights about US Meningococcal Vaccines Market

Request Free Sample

Key Players and Competitive Insights

The competitive landscape of the US Meningococcal Vaccines Market consists of various players striving to capture a significant share in a sector characterized by rapid advancements in vaccine technology and increasing awareness of meningococcal diseases. The market is influenced by several factors, including the prevalence of meningococcal infections, government vaccination initiatives, and the growing demand for preventive healthcare measures.

Companies in this sector are focusing on research and development to introduce innovative formulations and new vaccines, which cater to diverse age groups and high-risk populations. The competitive dynamics are also shaped by the regulatory environment, collaborations between firms and health organizations, as well as market access strategies to ensure broader distribution of their products.

Novartis has established a strong presence in the US Meningococcal Vaccines Market, leveraging its extensive experience and robust product portfolio. The company is recognized for its commitment to addressing public health needs with innovative vaccine solutions, particularly for meningococcal infections that pose significant health risks.

Novartis's strengths lie in its strong research and development capabilities, allowing it to bring advanced vaccine technologies to market efficiently. Additionally, its established relationships with healthcare providers and regulatory bodies enhance its ability to navigate market challenges effectively.

Novartis's reputation and credibility within the pharmaceutical industry further bolster its competitive position in the US Meningococcal Vaccines Market, providing a solid foundation for continued growth and success.

AstraZeneca also plays a vital role in the US Meningococcal Vaccines Market, focusing on the development of vaccines that cater to the specific needs of various segments of the population, particularly adolescents and young adults, who are at higher risk for infections. Key products and services offered by AstraZeneca in this domain emphasize safety and efficacy, catering to the growing demand for preventive healthcare solutions.

The company has successfully established a strong market presence, marked by its proactive approach to vaccine research and partnerships with public health organizations. Among its strengths is AstraZeneca’s commitment to innovation, which is evident in its ongoing efforts to enhance existing products and develop new candidates.

Furthermore, the company has engaged in strategic mergers and acquisitions that have strengthened its portfolio in immunotherapy and vaccine development, positioning it favorably in the competitive landscape of meningococcal vaccines within the US region.

Key Companies in the US Meningococcal Vaccines Market market include

Industry Developments

The US Meningococcal Vaccines Market has witnessed significant developments recently, particularly with the rising awareness of meningococcal diseases. Companies such as Merck and Pfizer are actively involved in expanding their vaccine portfolios.

In March 2023, the Centers for Disease Control and Prevention (CDC) emphasized the importance of meningococcal vaccination among adolescents, leading to a surge in demand for vaccines from companies like GlaxoSmithKline and AstraZeneca. Recent innovations from CureVac and Moderna in messenger RNA technology have also drawn attention, potentially revolutionizing vaccine development in this space.

As of July 2023, Amgen announced an agreement to collaborate with VBI Vaccines to enhance their R&D efforts in meningococcal vaccines. In October 2022, Novartis expanded its market presence by acquiring a small biotech firm focused on pneumococcal and meningococcal vaccine technology, a move aimed at strengthening its portfolio against infectious diseases.

The Serum Institute of India is ramping up production levels to meet the growing demands in the US, further reflecting the market's robust growth trajectory. Overall, the US Meningococcal Vaccines Market is evolving with promising innovations and strategic collaborations among leading companies.

Market Segmentation

Meningococcal Vaccines Market Age Group Outlook

Infants
Children
Adolescents
Adults

Meningococcal Vaccines Market Vaccine Type Outlook

Monovalent Vaccines
Multivalent Vaccines
Conjugate Vaccines

Meningococcal Vaccines Market Administration Route Outlook

Intramuscular
Subcutaneous
Oral

Meningococcal Vaccines Market Distribution Channel Outlook

Hospitals
Clinics
Pharmacies

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	0.93(USD Billion)
MARKET SIZE 2024	1.02(USD Billion)
MARKET SIZE 2035	1.65(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.469% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Novartis, AstraZeneca, Merck, GlaxoSmithKline, CureVac, Moderna, Pfizer, Kamada, Amgen, Valneva, VBI Vaccines, Serum Institute of India, Bavarian Nordic, Sanofi Pasteur
SEGMENTS COVERED	Vaccine Type, Age Group, Administration Route, Distribution Channel
KEY MARKET OPPORTUNITIES	Increasing vaccine awareness campaigns, Expansion of immunization programs, Development of combination vaccines, Rising adolescent vaccination rates, Enhanced distribution channels and partnerships
KEY MARKET DYNAMICS	increased vaccination campaigns, rising awareness of meningococcal diseases, government initiatives and funding, introduction of new vaccine formulations, growing prevalence of bacterial infections
COUNTRIES COVERED	US

FAQs

What is the expected market size of the US Meningococcal Vaccines Market in 2024?

The US Meningococcal Vaccines Market is expected to be valued at 1.02 billion USD in 2024.

What will the market be valued at by the year 2035?

By 2035, the US Meningococcal Vaccines Market is expected to reach a value of 1.65 billion USD.

What is the projected CAGR for the US Meningococcal Vaccines Market from 2025 to 2035?

The expected compound annual growth rate (CAGR) for the US Meningococcal Vaccines Market from 2025 to 2035 is 4.469%.

Which segment of the market is expected to dominate in terms of market share?

The Multivalent Vaccines segment is expected to dominate the market with a valuation of 0.4 billion USD in 2024 and 0.62 billion USD in 2035.

Who are the key players in the US Meningococcal Vaccines Market?

Key players in the market include Novartis, AstraZeneca, Merck, GlaxoSmithKline, and Pfizer, among others.

How is the Monovalent Vaccines segment expected to grow by 2035?

The Monovalent Vaccines segment is projected to grow from 0.3 billion USD in 2024 to 0.5 billion USD by 2035.

What are the growth drivers for the US Meningococcal Vaccines Market?

Key growth drivers include the rising awareness of meningococcal diseases and increasing vaccination rates.

What impacts could the current global scenario have on the Meningococcal Vaccines Market?

Various global factors may affect supply chains and vaccination initiatives within the Meningococcal Vaccines Market.

What will the Conjugate Vaccines segment be valued at in 2035?

By 2035, the Conjugate Vaccines segment is expected to reach a value of 0.53 billion USD.

How is the market for Meningococcal Vaccines expected to perform from 2025 to 2035?

The market is anticipated to show steady growth from 2025 to 2035, driven by innovations and increased healthcare investments.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027